CORRECTING and REPLACING – Novocure to Report Third Quarter 2016 Financial Results

September 30, 2016 12:39 PM Eastern Standard Time

ST. HELIER, Jersey, Sept. 30, 2016 (GLOBE NEWSWIRE) — In a press release issued under the same headline earlier today by Novocure, Ltd. (Nasdaq:NVCR), please note that the first paragraph should say “the three and nine months ended Sept. 30, 2016” rather than “the three and six months ended Sept. 30, 2016” as previously stated. The corrected release follows:

Novocure to Report Third Quarter 2016 Financial Results

Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended Sept. 30, 2016, at 8 a.m. EDT on Wednesday, Nov. 2, 2016.

The conference call can be accessed by dialing 877-726-5929 for domestic callers and 530-379-4648 for international callers, using the conference ID 76871474. The webcast can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investors-relations, and will be available for replay for at least 14 days following the call.

About Novocure

Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, www.novocure.com or follow us at www.twitter.com/novocure.

Contacts

Media and Investor Contact:
Ashley Cordova
212-767-7558
acordova@novocure.com